Cart
×
Santhera Update on SIDEROS Clinical Trial
View Santhera’s Duchenne Community Letter
Update on the Vamorolone Program
We will provide an update on the scientific rationale for use of vamorolone, and share some results from our open-label Long Term Extension study. The very important pivotal clinical trial […]
The CureDuchenne Biobank Webinar
Shape Therapeutics, Inc. raises $35.5M Series A financing, led by NEA and announces the formation of a world-class Scientific Advisory Board, to advance a first-in-class RNA editing gene therapy platform focused on curing genetic diseases.
The Shape Therapeutics RNAfixTM editing platform uses fully human components and avoids risks associated with in vivo CRISPR-based technologies. The SAB, comprised of industry pioneers in the field of […]
CureDuchenne Biobank
AUTHOR: Romina Foster-Bonds (View Spanish Version Below) CureDuchenne has made a significant commitment to develop and maintain a biobank dedicated to Duchenne muscular dystrophy — the CureDuchenne Biobank. The CureDuchenne […]
cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), publishes research in the journal PLOS ONE providing quantitative insights to assist the […]
Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophy
NEWPORT BEACH, CALIF. – (October 12, 2019) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular […]
24th International Annual Congress of the World Muscle Society (WMS) Day 5 Blog
The last day 24th International Annual Congress of the World Muscle Society (WMS) opened with a talk touching on a growing field in neuromuscular disorders – the use of digital […]
24th International Annual Congress of the World Muscle Society (WMS) Day 4 Blog
Many therapies being developed for Duchenne muscular dystrophy, including gene therapies, gene editing, and some exon-skipping approaches, rely on use of a virus to get the therapeutic components inside of […]